1. Home
  2. VYNE vs MTC Comparison

VYNE vs MTC Comparison

Compare VYNE & MTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VYNE
  • MTC
  • Stock Information
  • Founded
  • VYNE 2003
  • MTC 2015
  • Country
  • VYNE United States
  • MTC Hong Kong
  • Employees
  • VYNE N/A
  • MTC N/A
  • Industry
  • VYNE Biotechnology: Pharmaceutical Preparations
  • MTC Computer Software: Prepackaged Software
  • Sector
  • VYNE Health Care
  • MTC Technology
  • Exchange
  • VYNE Nasdaq
  • MTC Nasdaq
  • Market Cap
  • VYNE 41.9M
  • MTC 36.3M
  • IPO Year
  • VYNE 2018
  • MTC 2019
  • Fundamental
  • Price
  • VYNE $2.32
  • MTC $1.50
  • Analyst Decision
  • VYNE Strong Buy
  • MTC
  • Analyst Count
  • VYNE 2
  • MTC 0
  • Target Price
  • VYNE $6.88
  • MTC N/A
  • AVG Volume (30 Days)
  • VYNE 129.4K
  • MTC 127.1K
  • Earning Date
  • VYNE 02-27-2025
  • MTC 02-11-2025
  • Dividend Yield
  • VYNE N/A
  • MTC N/A
  • EPS Growth
  • VYNE N/A
  • MTC N/A
  • EPS
  • VYNE N/A
  • MTC 1.16
  • Revenue
  • VYNE $493,000.00
  • MTC N/A
  • Revenue This Year
  • VYNE $28.30
  • MTC N/A
  • Revenue Next Year
  • VYNE N/A
  • MTC N/A
  • P/E Ratio
  • VYNE N/A
  • MTC $1.44
  • Revenue Growth
  • VYNE 39.27
  • MTC N/A
  • 52 Week Low
  • VYNE $1.57
  • MTC $0.18
  • 52 Week High
  • VYNE $4.30
  • MTC $12.90
  • Technical
  • Relative Strength Index (RSI)
  • VYNE 36.13
  • MTC 53.25
  • Support Level
  • VYNE $2.34
  • MTC $1.43
  • Resistance Level
  • VYNE $3.00
  • MTC $1.69
  • Average True Range (ATR)
  • VYNE 0.27
  • MTC 0.11
  • MACD
  • VYNE -0.08
  • MTC -0.05
  • Stochastic Oscillator
  • VYNE 8.24
  • MTC 19.35

About VYNE VYNE Therapeutics Inc.

VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.

About MTC MMTec Inc.

MMTEC Inc provides Internet-based technology services and solutions to the Chinese language speaking hedge funds, mutual funds, registered investment advisors, proprietary trading groups, and brokerage firms engaging in securities market transactions and settlements globally. It offers complete suite trading solutions, including services such as fund establishment, issuance, custody, transaction, and settlement. The Company currently has two operating segments, Gujia, MM Future, MMBD Advisory and HC Securities, and MM Global. It generates maximum revenue from the Gujia segment. Gujia segment provides market data services and investor relations management services to customers in China.

Share on Social Networks: